NFE2L2 and amyotrophic lateral sclerosis: In studies of ischemic stroke and ALS models, edaravone (Eda) (Figure 1E), a cerebroprotective agent, was also approved for treatment of amyotrophic lateral sclerosis (ALS) and has been reported as an Nrf2 activator [7,8,9].